The one trial that the review considered iffy on meeting the categorical efficacy endpoint, based on how dropouts are treated, is the BLOOM DM trial composed of type 2 diabetics. The significant improvement in glycemic control will more than make up for the marginal weight loss efficacy, in my opinion,…